A Study to Evaluate the Effect and Tolerance of Musclin™ (Thymol) in Healthy Subjects

Last updated: December 5, 2018
Sponsor: Innovus Pharmaceuticals, Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Healthy Volunteers

Treatment

N/A

Clinical Study ID

NCT03767504
INNV-MS1000-001
  • Ages > 40
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This study is to evaluate the effect and tolerance of a thymol containing dietary supplement, Musclin, in healthy adults.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Healthy volunteer > 40 years (adult)

  2. Systolic blood pressure 90-140 mmHg upon screening

  3. Subject has provided written informed consent

  4. Subject is willing to undergo the procedures outlined in this study

  5. Subjects BMI is within 18-28.

  6. Subjects of childbearing potential must use a hormonal method of birth control,single-barrier method or a double-barrier method of birth control throughout the studyor be documented as medically sterile.

Exclusion

Exclusion Criteria:

  1. Subject has clinically significant deviation from normal in any organ system.

  2. Subject has a clinically significant deviation from normal in any laboratory testexcept high cholesterol.

  3. Pregnant, breastfeeding, or planned pregnancy during the study duration.

  4. Known liver, renal or muscle diseases.

  5. History of hypertensive or currently taking anti-hypertensive medications.

  6. Presence or history of specific heart conditions.

  7. Currently taking anti-thyroid or thyroid replacement medications.

  8. Currently taking any creatinine kinase lowering drug or supplement.

  9. Use of investigational drug within the previous 30 days.

  10. Use of herbal supplements, and/or over-the-counter (OTC) medication, dietarysupplements (vitamins included) within 2 weeks prior to initial dosing.

  11. Known allergies or intolerance to ingredients in Musclin™

  12. Any condition which would interfere with the subject's ability to provide informedconsent, to comply with study instructions, or which might confound the interpretationof the study results.

Study Design

Total Participants: 20
Study Start date:
November 13, 2018
Estimated Completion Date:
February 28, 2019

Study Description

This study will be an open label, uncontrolled, ascending dose clinical trial to assess the tolerance and effect of orally ingested Musclin, 20 mg thymol per capsule, in healthy adult subjects. In addition, this study will evaluate whether Musclin has an effect on creatine kinase and myostatin levels. The study will aim to enroll 20 consenting men and women. Consented subjects will ingest 2 capsules of Musclin daily for 30 days and increase to 4 capsules daily for an additional 30 days . Physical assessments and biological samples will be collected at baseline (day 0) and at end of treatment (d 60). Surveys to include reported stamina and energy levels will be collected at baseline, prior to increased dosage (d 30) and end of treatment period. Risk to participants is expected to be minimal and will be outlined through an informed consent.

Connect with a study center

  • Palm Beach Research Center

    West Palm Beach, Florida 33409
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.